Physician profile
Jacobo Pena
NPI 1598015620
$12,707.56
in general payments reported to CMS, 2019-2025
45 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $1,115 · 2021: $2,100 · 2022: $3,088 · 2023: $2,176 · 2024: $1,500 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,054.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,395.45 | 2020-2025 | Xifaxan, Relistor, Trulance |
| Abbvie INC. | $1,769.04 | 2019-2025 | |
| Novo Nordisk INC | $875.28 | 2021-2024 | Ozempic, Rybelsus |
| Amgen INC. | $875.11 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $715.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $591.45 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $542.89 | 2019-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $534.29 | 2019-2023 | |
| Exact Sciences Corporation | $430.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $360.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $344.97 | 2019-2024 | Lokelma, Farxiga, Fasenra |
| Horizon Therapeutics Plc | $316.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $266.37 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Ironwood Pharmaceuticals, INC | $239.22 | 2021-2024 | |
| Abbott Laboratories | $206.83 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $194.35 | 2019-2020 | |
| Daiichi Sankyo INC. | $194.14 | 2021-2023 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $189.79 | 2022-2024 | Austedo Xr, Austedo, Ajovy |
| Astellas Pharma US INC | $179.68 | 2021-2025 | Veozah |
| Pfizer INC. | $165.06 | 2020-2025 | |
| Amarin Pharma, INC. | $110.03 | 2020-2022 | |
| Lilly USA, LLC | $104.01 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.75 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.81 | 2022-2023 | Trintellix |
| Intra-Sana Laboratories | $98.33 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Nestle Healthcare Nutrition INC. | $89.75 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $87.41 | 2019-2020 | |
| Lundbeck LLC | $82.90 | 2022-2024 | Rexulti |
| Esperion Therapeutics, INC. | $69.23 | 2022-2023 | Nexletol |
| Mylan Specialty L.P. | $47.80 | 2023 | Yupelri |
| Dexcom, INC. | $44.79 | 2024 | Dexcom G6 Transmitter |
| Global Blood Therapeutics, INC. | $42.90 | 2022 | |
| Aimmune Therapeutics, INC. | $42.86 | 2025 | Zenpep |
| Kowa Pharmaceuticals America, INC. | $42.30 | 2019-2025 | Zoryve |
| Mannkind Corporation | $35.29 | 2019 | |
| Insulet Corporation | $29.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.79 | 2024 | |
| Valinor Pharma, LLC | $24.56 | 2025 | Movantik |
| Nevro Corp. | $23.79 | 2021 | |
| Biogen, INC. | $23.65 | 2020 | |
| Axsome Therapeutics, INC. | $20.37 | 2025 | Symbravo |
| Genentech USA, INC. | $19.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.05 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $15.49 | 2025 | Gemtesa |
| Impel Pharmaceuticals INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacobo Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.